RF 1051 data

The Emeryville, Calif., company announced that pilot Phase I results in 17 obese people demonstrate promising action of the orally administered steroid.

RF 1051 appears to modulate mitochondrial respiration and normalize glucose levels in db/db mice, with no apparent side effects. In the pilot trial, adults who received the steroid for 10 weeks lost about 5 percent of initial body fat, compared to no change after placebo for 10 weeks. Food intake did not change during the trial. Doses up to four grams were tested. ...